About : Calliditas Therapeutics

---

Address : Kungsbron 1, D5, Stockholm, Sweden, 111 22
Tel : 46 84 11 30 05
URL : https://www.calliditas.se
Code : CALT, ISIN : US13124Q1067, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 05_Jun_2020
Employee Count : 217

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.